Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Our mission is to invent and deliver groundbreaking treatments and cure-based medical solutions that will dramatically improve the lives of patients and their families.

Our vision is to be a leader in healthcare innovation, providing novel treatments and working to eliminate preventable diseases.

Kiora Pharmaceuticals has been recognized with dozens of awards for its commitment to innovation and excellence in healthcare. In 2019, the company was awarded the Sabin-Asch Award for Excellence in Medical Research, and in 2020, it was nominated for the Prix Galien Award for Drug Discovery and Development.